{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:02:11Z","timestamp":1774587731612,"version":"3.50.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This single-center retrospective study explores the safety and efficacy of <jats:sup>177<\/jats:sup>Lu-DOTATATE in children and young adult population with metastatic\/inoperable neuroendocrine tumors (NETs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>This study is a retrospective analysis of all children and young adult patients (\u226429 years) with advanced inoperable\/metastatic epithelial or nonepithelial NETs who were administered a median of 4 cycles of <jats:sup>177<\/jats:sup>Lu-DOTATATE therapy and low-dose oral capecitabine as a radiosensitizer every 8\u201312 weeks, except 2 patients who received CAPTEM chemotherapy. The radiological response was assessed using RECIST 1.1 on interim and end-of-treatment <jats:sup>68<\/jats:sup>Ga-DOTANOC PET\/CT. The primary endpoint was objective response rate, whereas disease control rate, toxicity profile, progression-free survival, and overall survival were secondary endpoints.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Nineteen biopsy-proven NET patients (median age, 22 \u00b1 10 years) with 8 of them adolescents (10\u201318 years) and the remaining young adults (19\u201329 years) were included. Fourteen patients had gastroenteropancreatic neuroendocrine tumor (pancreas being most common primary site), whereas the rest had non\u2013gastroenteropancreatic neuroendocrine tumor. A total of 65 cycles of <jats:sup>177<\/jats:sup>Lu-DOTATATE (range, 1\u20136 cycles) were administered with a median cumulative activity of 600 mCi (range, 100\u20131000 mCi). The objective response rate and disease control rate were 41% and 94%, respectively. Grade 1 and 2 adverse events were observed in 14 (74%) and 5 (26%) of 19 patients, respectively. In a total of 8 events (42%), 4 events each of disease progression and death occurred during a median follow-up of 80.1 months with an estimated 5-year progression-free survival and overall survival of 54% (95% confidence interval, 30\u201378) and 63% (95% confidence interval, 39\u201387), respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>\n                                 <jats:sup>177<\/jats:sup>Lu-DOTATATE appears safe and effective in children and young adults with metastatic\/inoperable NETs. Large prospective trials are required to validate these results.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005233","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T05:00:17Z","timestamp":1716267617000},"page":"e312-e318","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Safety and Efficacy of 177Lu-DOTATATE in Children and Young Adult Population"],"prefix":"10.1097","volume":"49","author":[{"given":"Piyush","family":"Aggarwal","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swayamjeet","family":"Satapathy","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwani","family":"Sood","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harmandeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhagwant Rai","family":"Mittal","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadhna","family":"Lal","sequence":"additional","affiliation":[{"name":"Gastroenterology (Division of Pediatric Gastroenterology)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Gupta","sequence":"additional","affiliation":[{"name":"Surgical Gastroenterology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandan Krushna","family":"Das","sequence":"additional","affiliation":[{"name":"Clinical Hematology and Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thakur Deen","family":"Yadav","sequence":"additional","affiliation":[{"name":"Surgical Gastroenterology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama","family":"Walia","sequence":"additional","affiliation":[{"name":"Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1186\/s12885-018-5057-3","article-title":"Delays and routes to diagnosis of neuroendocrine tumours","volume":"18","year":"2018","journal-title":"BMC Cancer"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/pbc.22559","article-title":"Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006","volume":"56","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/MNM.0000000000001103","article-title":"177Lu-DOTATATE peptide receptor radionuclide therapy versus everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis","volume":"40","year":"2019","journal-title":"Nucl Med Commun"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"91","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2967\/jnumed.110.085100","article-title":"177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma","volume":"52","year":"2011","journal-title":"J Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"836230","DOI":"10.3389\/fped.2022.836230","article-title":"A phase II trial of a personalized, dose-intense administration schedule of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma-LuDO-N","volume":"10","year":"2022","journal-title":"Front Pediatr"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1007\/s00259-020-04741-x","article-title":"A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3390\/ijms24021418","article-title":"The complex histopathological and immunohistochemical spectrum of neuroendocrine tumors\u2014an overview of the latest classifications","volume":"24","year":"2023","journal-title":"Int J Mol Sci"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"e29056","DOI":"10.1002\/pbc.29056","article-title":"Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children","volume":"68","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1097\/RLU.0000000000001816","article-title":"Concomitant 177Lu-DOTATATE and capecitabine therapy in patients with advanced neuroendocrine tumors: a long-term-outcome, toxicity, survival, and quality-of-life study","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib13-20250621","first-page":"1167","article-title":"(177)Lu-DOTATATE plus radiosensitizing capecitabine versus octreotide long-acting release as first-line systemic therapy in advanced grade 1 or 2 gastroenteropancreatic neuroendocrine tumors: a single-institution experience","volume":"7","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00259-020-05004-5","article-title":"Long-term outcome of \u201csandwich\u201d chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG-and SSTR-avid aggressive disease","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.3390\/cancers14205049","article-title":"Pediatric neuroendocrine neoplasms: rare malignancies with incredible variability","volume":"14","year":"2022","journal-title":"Cancer"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.5858\/2008-132-1079-PAMLTI","article-title":"Primary and metastatic lung tumors in the pediatric population: a review and 25-year experience at a large children\u2019s hospital","volume":"132","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/cen.14727","article-title":"Update on the clinical management of multiple endocrine neoplasia type 1","volume":"97","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12664-017-0808-7","article-title":"Trends in diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in India: a report of multicenter data from a web-based registry","volume":"36","year":"2017","journal-title":"Indian J Gastroenterol"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1097\/RLU.0000000000002368","article-title":"Management of primary lymph nodal gastrinoma with liver metastases resulting in Zollinger-Ellison syndrome","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib21-20250621","article-title":"Pediatric neuroendocrine carcinoid tumors: management, pathology, and imaging findings in a pediatric referral center","volume":"64","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1097\/RLU.0b013e318252d2c3","article-title":"Usual and unusual neuroendocrine tumor metastases on (68)Ga-DOTANOC PET\/CT: a pictorial review","volume":"38","year":"2013","journal-title":"Clin Nucl Med"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/ijc.30400","article-title":"The epidemiology of metastases in neuroendocrine tumors","volume":"139","year":"2016","journal-title":"Int J Cancer"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1159\/000513249","article-title":"Unique metastatic patterns in neuroendocrine neoplasms of different primary origin","volume":"111","year":"2021","journal-title":"Neuroendocrinology"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.2967\/jnumed.120.258772","article-title":"Surgical feasibility, determinants, and overall efficacy of neoadjuvant 177Lu-Dotatate PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"687925","DOI":"10.3389\/fonc.2021.687925","article-title":"Value of peptide receptor radionuclide therapy as neoadjuvant treatment in the management of primary inoperable neuroendocrine tumors","volume":"11","year":"2021","journal-title":"Front Oncol"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2967\/jnumed.115.158899","article-title":"Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0,Tyr3]octreotate","volume":"56","year":"2015","journal-title":"J Nucl Med"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2967\/jnumed.110.075226","article-title":"Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors","volume":"51","year":"2010","journal-title":"J Nucl Med"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/MPH.0000000000000411","article-title":"Initial experience with gallium-68 DOTA-octreotate PET\/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma","volume":"38","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"1193880","DOI":"10.3389\/fnume.2023.1193880","article-title":"Case report: peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumors","volume":"3","year":"2023","journal-title":"Front Nucl Med"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11523-020-00784-0","article-title":"Updated efficacy and safety outcomes for patients with well-differentiated pancreatic neuroendocrine tumors treated with Sunitinib","volume":"16","year":"2021","journal-title":"Target Oncol"},{"key":"bib34-20250621","first-page":"1169970","article-title":"Long-term prognostic factors for PRRT in neuroendocrine tumors","volume":"10","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/cncr.34191","article-title":"Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu-octreotate peptide radionuclide therapy","volume":"128","year":"2022","journal-title":"Cancer"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"16932","DOI":"10.18632\/oncotarget.24524","article-title":"Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms","volume":"9","year":"2018","journal-title":"Oncotarget"},{"issue":"suppl_7","key":"bib37-20250621","first-page":"S410","article-title":"887O - First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: results of the OCLURANDOM trial","volume":"33","year":"2022","journal-title":"Ann Oncol"},{"key":"bib38-20250621","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.112.119347","article-title":"Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"54","year":"2013","journal-title":"J Nucl Med"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib40-20250621","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000362558","article-title":"Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up","volume":"99","year":"2014","journal-title":"Neuroendocrinology"},{"key":"bib41-20250621","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12308-015-0253-4","article-title":"Pediatric myelodysplastic syndromes","volume":"8","year":"2015","journal-title":"J Hematop"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:01:33Z","timestamp":1750532493000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005233"}},"subtitle":["A Single-Center Experience"],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005233","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,21]]}}}